Resultado de búsqueda
6 de may. de 2024 · News Releases. Events. Presentations. Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024. May 6, 2024 at 8:00 AM EDT. PDF Version. Expect to share initial clinical and translational data from the Phase 1 trial of LYL797, a ROR1-targeted CAR T‑cell product candidate, this quarter.
6 de may. de 2024 · SOUTH SAN FRANCISCO, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies...
13 de may. de 2024 · LYEL Lyell Immunopharma, Inc. Stock Price & Overview. Follow. 817 followers. $2.40 -0.06 ( -2.44%) 4:00 PM 05/13/24. NASDAQ | $USD | Post-Market: $2.35 -0.05 (-2.08%) 4:06 PM. Summary. Ratings....
Hace 5 días · Lyell Immunopharma Inc. LYEL:US. Nasdaq GS (USD) · Market closed. 2.77. +0.06 +2.21% As of 12:00 AM EDT 05/24/24. Prev. close. 2.71 USD. 2.77 USD. 3:58 PM. 9:30a 10:25a 11:20a 12:16p 1:11p 2:07p...
7 de may. de 2024 · Lyell Immunopharma (NASDAQ:LYEL) First Quarter 2024 Results Key Financial Results. Net loss: US$60.7m (loss narrowed by 9.4% from 1Q 2023). US$0.24 loss per share (improved from US$0.27 loss in...
20 de may. de 2024 · Pharmaceuticals & Biotech. Lyell Immunopharma NasdaqGS:LYEL Stock Report. Last Price. US$2.67. Market Cap. US$698.5m. 7D. 11.3% 1Y. -7.6% Updated. 20 May, 2024. Data. Company Financials +. 3 Analysts. LYEL Stock Overview. A clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors.
6 de may. de 2024 · Lyell Immunopharma reports a net loss of $60.7 million in Q1 2024 while experiencing a decrease in cash and marketable securities.
